Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults (≥ 18 years) at the time of signing informed consent form~2. Understand and voluntarily sign informed consent form~3. Able to adhere to study visit schedule and other protocol requirements~4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2~5. Absolute neutrophil count ≥ 1500 / mm³~6. Platelet count ≥ 100,000 / mm³~7. Resectable pancreatic adenocarcinoma~8. Pathologic diagnosis of pancreatic adenocarcinoma~Exclusion Criteria:~1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing informed consent form~2. A history of renal dysfunction (serum creatinine \> 1.8 mg/dL)~3. Presence of active infection~4. Untreated second malignancy~5. Pregnant or breast feeding females (A urine pregnancy test will be obtained in all women of child-bearing age at initial screening prior to study enrollment and administration of chemotherapy.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine / Cisplatin (Type: EXPERIMENTAL): Single arm study. All patients will receive gemcitabine and cisplatin as adjuvant therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).